posit readout soliri nmo
soliri achiev primari endpoint nmo pivot trial prevent
trial enrol patient random soliri mean annual
relaps rate prior enrol soliri result
improv time first adjud on-trial relaps rel
placebo adjud on-trial relaps placebo arm
adjud on-trial relaps treatment arm addit
patient soliri event free week compar
patient placebo soliri well-toler overal safeti profil
consist soliri trial specif patient year
equival ae sae rate lower soliri arm placebo
placebo patient vs soliri patient discontinu studi
sae meningococc infect either trial arm
thought stock step today news view
favor street investor mute expect
trial plan file near futur model approv
outlin nmo deep dive see ww sale potenti
base penetr relaps nmo market reflect
competit space next nmo catalyst roch antagonist
result expect octob mention preview note
primari endpoint time first relaps may prove
convinc endpoint practic physician
valuat maintain outperform rate increas tp
modest increas driven increas po assumpt nmo
indic risk thesi includ regulatori risks/delay posit
updat competitor
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
alexion biotechnolog compani focus research
develop commerci therapeut rare diseas
alexion drug soliri use treat patient complement
mediat disord product includ strensiq
abl convert major soliri patient prior
launch biosimilar continu strength gmg launch
posit nmo data increas pipelin valu
unabl convert major soliri patient
prior launch biosimilar eu/row weak gmg
trend failur nmo decreas pipelin valu
price sep rate outperform target price analyst martin auster
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
compani mention price
